Genetic variant near cytosolic phospholipase A2 associated with schizophrenia

Schizophrenia Research

Volumn 21, Issue 2, 1996, Pages 111-116

  Hudson, Craig J ^a   Kennedy, James L ^a   Gotowiec, Andrew ^a   Lin, Anna ^a   King, Nicole ^a   Gojtan, Katherine ^a   Macciardi, Fabio ^b   Skorecki, Karl ^c   Meltzer, Herbert Y ^d   Warsh, Jerry J ^a   Horrobin, David F ^e  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e Scotia Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Genetic association; Genetic polymorphism; Haplotype relative risk; Phospholipase A2; Schizophrenia

Indexed keywords

ARACHIDONIC ACID; PHOSPHOLIPASE A2; PROSTAGLANDIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSOL; GENETICS; HUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0030598906     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/0920-9964(96)00031-X     Document Type: Article

References (35)

1. Carlsson, A. (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1, 179-186.
2. Carlsson, M. and Carlsson, A. (1990) Interactions between glutaminergic and monoaminergic systems within the basal ganglia implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13, 272-276.
3. 2 from the human monocytic cell line U937. Proc. Natl. Acad. Sci. USA 87, 7708-7712.
4. 2+-dependent translocation domain with homology to PKC and GAP. Cell 65, 1043-1051.
5. Cochran, C.D. and Hale, W.D. (1985) College student norms on the brief symptom inventory. J. Clin. Psychol. 41, 777-779.
6. Dumuis, A., Sebben, M., Haynes, L., Pin, J.P. and Bockaert, J. (1988) NMDA receptors activate the arachidonic acid cascade system in striatal neurons. Nature 336, 68-70.
7. Falk, C.T. and Rubinstein, P. (1987) Haplotype relative risks; an easy reliable way to construct a proper control sample for risk calculations. Ann. Hum. Genet. 51, 227-233.
8. 2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol. Psychiatry 22, 421-426.
9. 2 activity in schizophrenia: a replication study. Biol. Psychiatry 28, 495-501.
10. 2 activity in schizophrenia. Schizophr. Res. 16, 1-6.
11. 2 enzymes: regulation and inhibition. Trends Pharmacol. Sci. 14, 92-98.
12. Glen, A.I.M., Glen, E.M.T., Horrobin, D.F. et al. (1994) A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr. Res. 12, 53-61.
13. Horrobin, D.F. (1977) Schizophrenia as a prostaglandin deficiency disease. Lancet ii, 936-937.
14. Horrobin, D.F. (1980) Schizophrenia: a biochemical disorder. Biomedicine 32, 54-55.
15. Horrobin, D.F., Glen, A.I.M. and Vaddadi, K.S. (1994) The membrane hypothesis of schizophrenia. Schizophr. Res. 13, 195-207.
16. Hudson, C.J., Young, T., Li, P.P. and Warsh, J.J. (1993) CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse 13, 278-293.
17. Hudson, C.J., Lin, A., Cogan, S., Cashman, F. and Warsh, J.J. (in press) The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia? Biol. Psychiatry.
18. 2 in brain cortical cultures. Biochem. J. 310, 83-90.
19. Min-induced intestinal neoplasia. Cell 81, 957-966.
20. Meltzer, H.Y. (1989) Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99, S18-S277.
21. Meltzer, H.Y. (1992) Treatment of the neuroleptic non-responsive schizophrenic patient. Schizophr. Bull. 18, 515-542.
22. 2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 38, 263-274.
23. Needleman, P., Turk, J., Jakschik, B.A., Morrison, A.R. and Lefkowith, J.B. (1986) Arachidonic acid metabolism. Annu. Rev. Biochem. 55, 69-102.
24. 2 activity in schizophrenics and other psychiatric patients. Biol. Psychiatry 34, 641-649.
25. Pettegrew, J.W., Keshavan, M.S., Panchalingam, K., Strychor, S., Kaplan, D.B., Tretta, M.G. and Allen, M. (1991) Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. Arch. Gen. Psychiatry 48, 563-568.
26. 2). Nucleic Acids Res. 18, 7468.
27. 2-dopamine receptors on arachidonic acid release and cyclic AMP production in striatal neurons. J. Neurochem. 62, 944-949.
28. 4 receptors elevated in schizophrenia. Nature 365, 441-445.
29. Spitzer, R.L., Williams, J.B.W. and Gibbons, M. (1986) Structured Clinical Interview for DSM-III-R (SCID). New York State Psychiatric Institute, Biometric Research, New York.
30. Stanley, J.A., Williamson, P.C., Drost, D.J., Carr, T.J., Rylett, R.J., Malla, A. and Thompson, R.T. (1995) An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch. Gen. Psychiatry 52, 399-406.
31. Strosznajder, J., Samochocki, M. and Duran, M. (1994) Serotonin, a potent modulator of arachidonic acid turnover, interaction with glutamatergic receptor in brain cortex. Neurochem. Int. 25, 193-199.
32. 2 gene in human and rat: chromosomal localization and polymorphic markers. Genomics 26, 138-141.
33. Terwilliger, J.D. and Ott, J. (1992) A Haplotype-based 'Haplotype Relative Risk' approach to detecting allelic associations. Hum. Hered. 42, 337-346.
34. Van Kammen, D., Yao, J. and Goetz, K. (1989) Polyunsaturated fatty acids, prostaglandins, and schizophrenia. Ann. NY Acad. Sci. 559, 411-423.
35. Yao, J.K., Van Kammen, D.P. and Welker, J.A. (1994) Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr. Res. 13, 217-226.